Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026 Business Wire - Thu Jun 18, 5:59AM CDT

Bristol Myers Squibb (NYSE: BMY) will announce results for the second quarter of 2026 on Thursday, July 30, 2026. Company executives will review financial results with the investment community...

BMY : 54.00 (-2.32%)
Bristol Myers Squibb Announces Dividend Business Wire - Wed Jun 17, 3:16PM CDT

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...

BMY : 54.00 (-2.32%)
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease Business Wire - Mon Jun 8, 5:59AM CDT

Multiple myeloma is a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions ...

BMY : 54.00 (-2.32%)
ICFI
3 Value Stocks We Think Twice About StockStory - Wed Jun 3, 11:39PM CDT

3 Value Stocks We Think Twice About

MTG : 26.06 (-0.72%)
ICFI : 66.51 (-7.88%)
BMY : 54.00 (-2.32%)
Bullish - green stock market chart with arrow up day trade by Quality Stock Arts via Shutterstock
Is Bristol-Myers Squibb Stock Underperforming the Dow? Barchart - Tue Jun 2, 10:48PM CDT

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

LLY : 1,098.57 (-1.21%)
$DOWI : 51,564.70 (unch)
BMY : 54.00 (-2.32%)
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma Business Wire - Tue Jun 2, 7:00AM CDT

Interim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO ® 2026 ...

BMY : 54.00 (-2.32%)
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) Business Wire - Mon Jun 1, 5:59AM CDT

Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population ...

BMY : 54.00 (-2.32%)
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma Business Wire - Mon Jun 1, 5:55AM CDT

First-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL)

BMY : 54.00 (-2.32%)
BMY
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1 StockStory - Sun May 31, 10:31PM CDT

Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1

BMY : 54.00 (-2.32%)
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma Business Wire - Fri May 29, 7:00AM CDT

First Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO ® 2026 SUCCESSOR-2 data reinforce...

BMY : 54.00 (-2.32%)

Barchart Exclusives

Microsoft vs. Nvidia: Which AI Giant Is the Better Dividend Stock for the Long Haul? Barchart - Fri Jun 19, 6:00PM CDT
Microsoft and NVIDIA are AI giants, but which stock is the better buy? Compare growth, valuation, dividends, and Wall Street ratings. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.